Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group

Luca Laurenti, Marino Gentile, Alessandra Tedeschi, Yair Herishanu, Adir Shaulov, Riva Fineman, Sandra Bašić-Kinda, Ariel Aviv, Ewa Wasik-Szczepanek, Ozren Jaksic, Mihnea Zdrenghea, Uri Greenbaum, Inga Mandac, Martin Simkovic, Marta Morawska, Ohad Benjamini, Martin Spacek, Anatoly Nemets, Osnat Bairey, Livio TrentinRosa Ruchlemer, Oana Stanca Ciocan, Michael Doubek, Lev Shvidel, Nagib Dali, Fátima Mirás, Anne De Meûter, Maria Dimou, Francesca R. Mauro, Marta Coscia, Horia Bumbea, Róbert Szász, Tamar Tadmor, Odit Gutwein, Massimo Gentile, Lydia Scarfò, Paolo Sportoletti, Eva Gimeno Vázquez, Juan Marquet, Sarit Assouline, Maria Papaioannou, Andrei Braester, Luciano Levato, Michael Gregor, Gian M. Rigolin, Javier Loscertales, Angeles Medina Perez, Marten R. Nijziel, Viola M. Popov, Rosa Collado, Irma Slavutsky, Gilad Itchaki, Shimrit Ringelstein, Neta Goldschmidt, Chava Perry, Shai Levi, Aaron Polliack, Paolo Ghia

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

In recent years, considerable progress has been made in frontline therapy for elderly/physically unfit patients with CLL. The combination of obinutuzumab and chlorambucil (O-Clb) has been shown to prolong progression free survival (PFS, median PFS-31.5 months) and overall survival (OS) compared to chlorambucil alone. More recently, obinutuzumab given in combination with either ibrutinib or venetoclax improved PFS but not OS when compared to O-Clb. In this retrospective multinational, multicenter co-operative study, we evaluated the efficacy and safety of frontline treatment with O ± Clb in unfit patients with CLL, in a “real-world” setting. Patients with documented del (17p13.1)/TP53 mutation were excluded. A total of 437 patients (median age, 75.9 years; median CIRS score, 8; median creatinine clearance, 61.1 mL/min) were included. The clinical overall response rate was 80.3% (clinical complete and partial responses in 38.7% and 41.6% of patients, respectively). Median observation time was 14.1 months and estimated median PFS was 27.6 months (95% CI, 24.2-31.0). In a multivariate analysis, high-risk disease [del (11q22.3) and/or IGHV-unmutated], lymph nodes of diameter > 5 cm, obinutuzumab monotherapy and reduced cumulative dose of obinutuzumab, were all independently associated with shorter PFS. The median OS has not yet been reached and estimated 2-year OS is 88%. In conclusion, in a “real-world” setting, frontline treatment with O-Clb achieves PFS comparable to that reported in clinical trials. Inferior outcomes were noted in patients with del (11q22.3) and/or unmutated IGHV and those treated with obinutuzumab-monotherapy. Thus, O-Clb can be still considered as legitimate frontline therapy for unfit CLL patients with low-risk disease.
Lingua originaleEnglish
pagine (da-a)604-611
Numero di pagine8
RivistaAmerican Journal of Hematology
Volume95
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols
  • Chlorambucil
  • Chromosome Deletion
  • Chromosomes, Human, Pair 17
  • Disease-Free Survival
  • Female
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Male
  • Retrospective Studies
  • Survival Rate
  • Tumor Suppressor Protein p53

Fingerprint

Entra nei temi di ricerca di 'Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group'. Insieme formano una fingerprint unica.

Cita questo